RevealDx appoints contextflow as its exclusive distributor in the European Union and
selected territories. The companies also announce trial installation discounts for select
customers.
Seattle, WA – August 3, 2022 – Chest specialists RevealDx and contextflow announced today an
agreement for exclusive distribution of RevealDx’ products in the EU and other selected
territories. The companies will be launching their integrated solution at the upcoming IASLC
World Conference on Lung Cancer in Vienna in August.
RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of
lung nodules to receive the CE Mark. The company recently completed its pivotal clinical trial
which demonstrated significant improvement in both early detection of malignant nodules and
reduction in false positive nodules in both screening and incidental cohorts.* By integrating this
patented technology into clinical routine, healthcare providers can reduce unnecessary
procedures, cost and stress for patients with lung nodules. *publication Fall 2022
contextflow is an industry leader in AI-based medical devices for radiologists evaluating chest
CTs. Its core technology is SEARCH Lung CT, a clinical decision support system that automatically
detects, quantifies and visualizes key disease patterns and lung nodules in CTs of the lungs over
time, displaying relevant information directly in the radiologist’s PACS viewer. The tool is relevant
for the analysis of many suspected diseases, including interstitial lung disease (ILD), chronic
obstructive pulmonary disease (COPD) and lung cancer. By including RevealDx’ lung nodule
characterization technology into SEARCH Lung CT, contextflow strengthens its capabilities even
further in the area of lung cancer screening by providing not just quantifications but also
classification of lung nodule types.
Integrating RevealDx’ nodule characterization technology into SEARCH Lung CT was a logical
next step for both sides. As Chris Wood, CEO of RevealDx says, “We are thrilled to be partnering
with contextflow. They have developed the most comprehensive set of tools for reading chest CT
available today. Adding RevealAI-Lung to their system makes it far and away the best solution to
efficiently and accurately interpret these challenging lung cancer cases.”
Markus Holzer, CEO of contextflow continues, “The RevealAI-Lung software has been well
integrated into our software, creating a seamless experience for users. We recently launched our
nodule detection software and quickly realized that characterization of nodules is essential to
make a significant impact on patient care. Partnering with RevealDx adds a layer of detail that we
feel will become indispensable for reducing false positives and false negatives during lung
cancer screening as well as in standard clinical routine.”
To schedule a virtual demo or book an appointment at IASLC, contact sales@contextflow.com
About RevealDx
RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of
lung nodules to receive the CE Mark. RevealAI-Lung has been validated in clinical studies that
show improvement in diagnostic precision using our patented methods. Results demonstrate the
software can significantly accelerate lung cancer diagnosis and reduce unnecessary procedures.
About contextflow
contextflow is a spin-off of the Medical University of Vienna (MUW) and European research
project KHRESMOI, supported by the Technical University of Vienna (TU). Founded by a team of
AI and engineering experts in July 2016, the company has received numerous awards; most
recently, contextflow was named a Born Global Champion 2021 by the Austrian Chamber of
Commerce. Its clinical decision support software SEARCH Lung CT is CE Marked and available
for clinical use within Europe under the new MDR. contextflow.co